One-year Results After Single-center Water Vapor Thermal Therapy for Symptomatic Benign Prostatic Hyperplasia.

Hisar Intercontinental Hospital

Status: Completed

Conditions: Prostatic Hyperplasia

Treatments: Device: REZUM

Study type: Observational

Funder types: Other

Identifiers

NCT06257654

26.01.2024/24-2

Details and patient eligibility

About

Objective: Rezūm vapor ablation is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that uses injections of sterile water vapor directly into the prostate for tissue ablation. Although Rezūm is currently indicated for use in men with prostate sizes ≥30 and ≤80 ml, it is unclear how effective Rezūm is for men in urinary retention. The investigators sought to determine whether Rezūm is effective in the treatment of catheter-dependent urinary retention secondary to BPH.

Full description

The data of participants who underwent Rezūm operation with the diagnosis of BPH between 2021 and 2023 were evaluated retrospectively. The investigators evaluated procedure details and evaluated pre- and post-Rezūm (including International Prostate Symptom Score (IPSS), IPSS quality of life (IPSS-QOL), prostate volumes, maximum flow (Qmax), post-void residual urine volume, IEEF-5, ejaculation dysfunction). The investigators examined variables at 6 and 12 months).

Enrollment: 71 patients

Sex: Male

Ages: 40 to 100 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

-Benign prostatic hyperplasia

Exclusion criteria

• Prostate cancer
• Parkinson's disease,
• Neurogenic bladder
• Overactive bladder
• Bladder calculus,
• Bladder Tumor
• Urinary infection
• Alzheimer's disease

Trial design

71 participants in 1 patient group

singel

Treatment:

Device: REZUM